Key Research Findings: Cagrilintide has shown to reduce food intake and slow gastric emptying, mimicking the natural actions of amylin (Kapitza et al.)
Prevention and Treatment of Diabetes Complications with Gastric Surgery or Intensive Medicines (PRODIGIES) trial is an ongoing trial which may shed light on this issue (ClinicalTrials.gov Identifier: NCT01974544)
examined the efficacy of the empagliflozin/linagliptin single-pill combination as second-line therapy in patients with T2DM who were inadequately controlled on metformin [106]
Current treatments for HS include topical clindamycin, erythromycin, and gentamicin, oral antibiotics including tetracyclines, clindamycin, combined clindamycin and rifampicin, combined clindamycin and ofloxacin, biologics such as adalimumab, infliximab, secukinumab and off-label ustekinumab and brodalumab
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
What remains unknown Despite encouraging data, genuine unknowns exist: Effects beyond 6-9 months of continuous use have not been formally studied in animals or humans
